Press release
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Set to Reach $1.85 Billion by 2029 with 10.3% Yearly Growth
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
The rising prevalence of Parkinson's disease is expected to drive the growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market in the coming years. Parkinson's disease is a progressive neurological disorder that affects movement due to the loss of dopamine-producing cells in the brain. The rising prevalence of Parkinson's disease is attributed to an aging population, improved diagnosis, environmental factors such as toxins, genetic influences, and greater awareness of the condition. VMAT2 inhibitors assist in managing Parkinson's symptoms by controlling dopamine release and reducing tremors and dyskinesia. For example, in December 2022, the Parkinson's Foundation reported that nearly 90,000 people were diagnosed with Parkinson's disease in the U.S. that year, marking a 50% increase from the previous estimate of 60,000 annual diagnoses. Thus, the growing prevalence of Parkinson's disease is driving the expansion of the vesicular monoamine transporter 2 (VMAT2) inhibitor market.
Get Your Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report Here:
https://www.thebusinessresearchcompany.com/report/vesicular-monoamine-transporter-2-vmat2-inhibitor-global-market-report
How will the growth rate of the vesicular monoamine transporter 2 (vmat2) inhibitor market shape industry trends by 2034?
The vesicular monoamine transporter 2 (VMAT2) inhibitor market has been expanding at a rapid pace. It is projected to grow from $1.13 billion in 2024 to $1.25 billion in 2025, recording a CAGR of 10.6%. The historical growth of this market has been supported by the increasing prevalence of movement disorders, rising demand for effective treatment options, heightened awareness of tardive dyskinesia, a growing elderly population, and a preference for oral formulations.
The vesicular monoamine transporter 2 (VMAT2) inhibitor market is expected to grow rapidly, reaching $1.85 billion by 2029, with a CAGR of 10.3%. Growth factors include a rising incidence of neurodegenerative diseases, increasing adoption of targeted therapies, a focus on personalized medicine, increased investment in R&D, and greater awareness of psychiatric and movement disorders. Major trends include advancements in neurological research, improved drug formulations, the shift toward personalized medicine, next-generation VMAT2 inhibitors, and the integration of digital health technologies.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp
What trends are poised to drive the future success of the vesicular monoamine transporter 2 (vmat2) inhibitor market?
In the vesicular monoamine transporter 2 (VMAT2) inhibitors market, companies are focusing on creating innovative capsules to enhance drug stability, ensure precise dosing, and improve patient compliance. Neurocrine Biosciences Inc., a US-based biopharmaceutical company, launched Ingrezza Sprinkle (valbenazine) capsules in July 2024. This formulation is designed for patients with tardive dyskinesia and chorea associated with Huntington's disease who may experience difficulty swallowing. The Ingrezza Sprinkle capsules can be sprinkled on food or swallowed whole, providing an easier and more convenient way to administer the drug.
Which primary segments of the vesicular monoamine transporter 2 (vmat2) inhibitor market are driving growth and industry transformations?
The vesicular monoamine transporter 2 (VMAT2) inhibitor market covered in this report is segmented -
1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs
2) By Route Of Administration: Oral, Other Administrations
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By Application: Huntington's Disease, Tardive Dyskinesia, Other Applications
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Tetrabenazine: Huntington's Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment
2) By Deutetrabenazine: Huntington's Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders
3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders
4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21317
Which geographical regions are pioneering growth in the vesicular monoamine transporter 2 (vmat2) inhibitor market?
North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the influential players reshaping the vesicular monoamine transporter 2 (vmat2) inhibitor market landscape?
Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp
What Is Covered In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Global Market Report?
•Market Size Forecast: Examine the vesicular monoamine transporter 2 (vmat2) inhibitor market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the vesicular monoamine transporter 2 (vmat2) inhibitor market for a structured understanding.
•Key Players Overview: Analyze major players in the vesicular monoamine transporter 2 (vmat2) inhibitor market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the vesicular monoamine transporter 2 (vmat2) inhibitor market.
•Segment Contributions: Evaluate how different segments drive overall growth in the vesicular monoamine transporter 2 (vmat2) inhibitor market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the vesicular monoamine transporter 2 (vmat2) inhibitor market.
•Industry Challenges: Identify potential risks and obstacles affecting the vesicular monoamine transporter 2 (vmat2) inhibitor market.
•Competitive Landscape: Review strategic developments in the vesicular monoamine transporter 2 (vmat2) inhibitor market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Set to Reach $1.85 Billion by 2029 with 10.3% Yearly Growth here
News-ID: 3935317 • Views: …
More Releases from The Business Research Company
Non-Invasive Ventilators Market: Major Trends Reshaping the Future of the Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Non-Invasive Ventilators Industry Market Size Be by 2025?
The market size for non-invasive ventilators has seen consistent growth over the past few years. The market value is projected to increase from $2.91 billion in 2024 to $3.05 billion in 2025, reflecting a compound annual growth rate…
The Impact Of Increasing Chronic Disease Incidence On The Mobile C-Arm Market: A …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Mobile C-arm Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of the mobile c-arm has seen consistent growth in the recent past. The market value is projected to increase from $1.36 billion in 2024 to a higher $1.42 billion in 2025, with…
Lithotripsy Devices Market Expected to Achieve 5.4% CAGR by 2029: Growth Forecas …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Lithotripsy Devices Market Size By 2025?
In the past few years, the market size for lithotripsy devices has seen a steady increase. The forecasted growth is from $1.25 billion in 2024 to $1.3 billion in 2025, maintaining a compound annual growth rate (CAGR) of 4.2%.…
Top Trends Transforming the Laparoscopy Devices Market Landscape in 2025: New Ad …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Laparoscopy Devices Industry Market Size Be by 2025?
In recent years, the market size for laparoscopy devices has seen impressive growth. It is predicted to expand from $12.75 billion in 2024 to $13.49 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. This…
More Releases for VMAT2
Tardive dyskinesia Market is expected to reach USD 8.2 billion by 2034
Tardive dyskinesia (TD) is a neurological movement disorder caused primarily by long-term use of dopamine receptor-blocking agents, such as antipsychotics and certain antiemetics. It is characterized by involuntary, repetitive movements of the face, tongue, and limbs, often irreversible and severely affecting quality of life. With the rising prevalence of psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder-and the increased use of antipsychotic medications-TD has emerged as a…
Steady Expansion Forecast for Vesicular Monoamine Transporter 2 (VMAT2) Inhibito …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for vesicular monoamine transporter 2 (vmat2) inhibitor has experienced swift expansion recently. The market is projected to increase from a valuation of $1.13 billion in 2024 to $1.25 billion…
Evolving Market Trends In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibito …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Expected Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size During the Forecast Period?
The market for the vesicular monoamine transporter 2 (VMAT2) inhibitor has experienced swift expansion in the recent past. The market, which was valued at $1.13 billion in 2024, is slated to reach $1.25 billion in 2025,…
Global Tardive Dyskinesia Treatment Market 2025 | Breakthroughs in VMAT2 Inhibit …
Global Tardive Dyskinesia Treatment Market is expected to Reach a CAGR of 4% during the forecast period (2024-2031).
Tardive Dyskinesia Treatment Market is comprehensively covered in the DataM Intelligence report, which offers critical data, industry trends, and market intelligence. The study delves into the competitive environment, assessing leading players on their product portfolios, pricing, financial health, strategic growth initiatives, and geographic expansion.
Unlock exclusive insights with our detailed sample report (Please enter…
Vmat2 Inhibitor Market Massive Growth opportunity Ahead | Amgen,Regeneron Pharma …
Vmat2 Inhibitor market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Vmat2 Inhibitor Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as…
Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market to Regist …
Vesicular monoamine transporter 2 (VMAT2) is a membrane-embedded protein that is responsible for uptake of monoamines neurotransmitters such as dopamine, serotonin, norepinephrine, and histamines into the synaptic vesicles in monoaminergic neurons. Vesicular monoamine transporter proteins 2 are expressed in the central nervous system (CNS) and plays the crucial role in the signaling process between the monoamine neurons. VMAT2 is the only transporter that carries the cytoplasmic dopamine into the vesicles.…
